Aktie A2P4TG KINTOR PHARMACEUTICAL LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Kintor Pharmaceutical Limited

Aktien

A2P4TG

KYG5273B1077

9939

Markt geschlossen - Hong Kong S.E.
Andere Börsenplätze
 10:08:05 31.05.2024 		% 5 Tage % 1. Jan.
1,21 HKD -.--% Intraday Chart für Kintor Pharmaceutical Limited -5,47 % -25,77 %
24.05. Kintor Pharmaceutical's Medikament gegen androgene Alopezie erhält Zustimmung der Behörden; Aktienkurs schießt um 10% in die Höhe MT
24.05. Kintor Pharmaceutical Limited gibt bekannt, dass die klinische Studie der von ihr selbst entwickelten und potenziell erstklassigen Kx-826 Tinktur 1,0% zur Behandlung von androgenetischer Alopezie bei männlichen Erwachsenen ("AGA") in China (die "klinische Studie") kürzlich von der National Medical Products Administration (die "Nmpa") genehmigt wurde CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Kintor Pharmaceutical's Androgenic Alopecia Drug Gets Regulatory Nod; Share Prices Shoot 10%
Kintor Pharmaceutical Limited Announces That the Clinical Trial of Its In-House Developed and Potential First-In-Class Kx-826 Tincture 1.0% for the Treatment of Male Adult Androgenetic Alopecia ("Aga") in China (The "Clinical Trial") Was Cleared by the National Medical Products Administration (The "Nmpa") Recently
Kintor Pharmaceutical Limited Announces Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China Reaches Primary Endpoint
Kintor Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2023
Kintor Pharmaceutical's Trial of Androgenetic Alopecia Drug Cleared by Chinese Regulator
Kintor Pharmaceutical Limited Announces Phase Ib/III Clinical Trial of KX-826 and Minoxidil Combination Therapy for the Treatment of Men Adults Receives Clearance by China NMPA
Kintor Pharmaceutical Limited Announces Results of Phase III Clinical Trial of KX-826 Topline Treatment for Men Androgenetic Alopecia
Kintor Pharmaceutical Limited Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China
Kintor Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2023
Kintor Pharma Announces Completion of Patient Enrollment in Phase Ii Clinical Trial of Gt20029 for Treatment of Androgenetic Alopecia in China
Kintor Pharmaceutical Limited Announces Completion of First Patient Enrollment in Long-Term Safety Trial of Kx-826
Kintor Pharmaceutical Limited Appoints Ming Ming Cheung as Joint Company Secretary
Kintor Pharmaceutical Limited Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US
Kintor Pharmaceutical Limited Announces Successful Completion of Phase I Clinical Trial of GT1708F for Treatment of Hematological Malignancies in China
Kintor Pharmaceutical Limited Announces Completion of First Subject Enrollment in Phase II Clinical Trial of AR-PROTAC (GT20029 ) for Treatment of Men Androgenetic Alopecia in China
Kintor Pharmaceutical Limited Announces Management Changes
Kintor Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2022
Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China
Kintor Pharma's KX-826 and GT20029 for Treatment of Androgenetic Alopecia and Acne Presented at AAD 2023
Kintor Pharmaceutical Limited Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World's First Topical Use PROTAC Compound
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2P4TG Aktie
  4. Nachrichten Kintor Pharmaceutical Limited
  5. Andere Sprachen